Goldman Sachs
FNCH

Goldman Sachs’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Goldman Sachs’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-571
Closed -$8.22K – 6371
2022
Q4 		$8.22K Sell
571
-286
-33% -$9.56K ﹤0.01% 5769
2022
Q3 		$43K Sell
857
-293
-25% -$20.4K ﹤0.01% 5821
2022
Q2 		$98K Buy
+1,150
New +$98.4K ﹤0.01% 5872
2021
Q2 		– Sell
-1,971
Closed -$955K – 6643
2021
Q1 		$955K Buy
+1,971
New +$1M ﹤0.01% 4650

Other funds holding FNCH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Goldman Sachs's FNCH Position: Q1 2023 in Review

Goldman Sachs sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2023, closing a stake of 571 shares — an estimated $8.22K sold.

Goldman Sachs first reported a position in FNCH in Q1 2021 and held it in 4 quarters. The position peaked at $955K in Q1 2021. 33 funds tracked by Wall St. Rank hold FNCH as of Q1 2023.

  • Goldman Sachs reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 571 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2023, an estimated $8.22K.
  • Goldman Sachs first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Goldman Sachs's Finch Therapeutics Group, Inc. Common Stock position peaked at $955K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.